Physician profile
Jesse E Smith
NPI 1194742791
$15,797.59
in general payments reported to CMS, 2019-2025
18 companies · $261 in 2025
The $261 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $2,456 · 2021: $1,032 · 2022: $5,189 · 2023: $4,836 · 2024: $1,192 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Travel and Lodging: $2,093 · Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Travel and Lodging | $2,092.50 |
| Food and Beverage | $1,196.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dutch Ophthalmic, USA | $9,059.93 | 2022-2024 | Eva, Combined Machine, Tissueblue |
| Organogenesis INC. | $1,800.00 | 2020 | |
| Allergan, INC. | $1,338.20 | 2019-2022 | |
| Merz North America, INC. | $1,255.64 | 2019-2023 | Xeomin |
| Stryker Corporation | $745.74 | 2019-2025 | Na, Smartlock |
| Abbvie INC. | $681.39 | 2023-2025 | Botox |
| Intersect Ent, INC. | $351.09 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $158.63 | 2019-2025 | Exparel |
| Medtronic, INC. | $98.80 | 2024-2025 | Stealthstation S8 Platform, Propel |
| Karl Storz Endoscopy-America | $64.74 | 2019 | |
| Genzyme Corporation | $54.04 | 2022 | |
| Boston Scientific Corporation | $42.83 | 2024 | |
| Acclarent, INC | $42.51 | 2022-2023 | Relieva Spinplus |
| Integra Lifesciences Corporation | $36.70 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Kerecis Limited | $22.18 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $20.38 | 2025 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.